US biotech Moderna has signed a ten-year manufacturing collaboration with Lonza for its Covid-19 vaccine, mRNA-1273, as well as future Moderna products.

The biotech will leverage Lonza’s manufacturing in the United States and Switzerland beginning in June this year.

Moderna’s mRNA Covid-19 vaccine is one of the furthest along in clinical trials; it applied for FDA approval to progress to Phase II studies if . To date, the programme has received funding and support from the US Govt through BARDA, as well as through CEPI.

Moderna CEO Stéphane Bancel noted: “We are very pleased to partner with Lonza, which shares our commitment to rapidly addressing this pandemic which has created a global health crisis.

“This long-term strategic collaboration agreement will enable Moderna to accelerate, by ten-times, our manufacturing capacity for mRNA-1273 and additional products in Moderna’s large clinical portfolio.

Lonza’s global presence and expertise are critical as we scale at unprecedented speed. Our common goal is to potentially enable manufacturing of up to one billion doses of mRNA-1273.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Lonza chairman and interim CEO Albert M. Baehny added: “Moderna’s technology represents a significant opportunity to change the way we protect people against disease.

“The current pandemic illustrates the need to combine the best science with resilient supply chains that can scale.

“We are fully committed to leveraging our global network and experience in manufacturing technologies to support Moderna’s manufacture of mRNA-1273 as well as collaborating on future Moderna products.”